Found: 6
Select item for more details and to access through your institution.
Response to Miller et al: resistant mutations in CML and Ph(+) ALL - role of ponatinib.
- Published in:
- 2015
- By:
- Publication type:
- Letter to the Editor
Primary Results of the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase (CP) Chronic Myeloid Leukemia (CML).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S290, doi. 10.1016/j.clml.2019.07.235
- By:
- Publication type:
- Article
Bosutinib (BOS) vs Imatinib (IM) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Initial Results from the BFORE Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S316, doi. 10.1016/j.clml.2017.07.117
- By:
- Publication type:
- Article
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 9, p. 755, doi. 10.1002/ajh.24034
- By:
- Publication type:
- Article
Bosutinib in Combination With the Aromatase Inhibitor Letrozole: A Phase II Trial in Postmenopausal Women Evaluating First-Line Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 348, doi. 10.1634/theoncologist.2014-0021
- By:
- Publication type:
- Article
Bosutinib in Combination With the Aromatase Inhibitor Exemestane: A Phase II Trial in Postmenopausal Women With Previously Treated Locally Advanced or Metastatic Hormone Receptor-Positive/HER2-Negative Breast Cancer.
- Published in:
- Oncologist, 2014, v. 19, n. 4, p. 346, doi. 10.1634/theoncologist.2014-0022
- By:
- Publication type:
- Article